LLY AI Stock Analysis – Buy, Hold, or Avoid?
Eli Lilly and Company (LLY)
Fundamentals
Eli Lilly (LLY) shows exceptionally strong fundamental performance, marked by robust revenue growth, expanding profitability metrics, and a consistent record of earnings beats. The company's innovation-driven product pipeline and leadership in fast-growing therapeutic markets underpin both its current financial health and future prospects, though recent premium valuation demands careful consideration.
Financial Highlights
- Revenue
- Net Income
- Net Margin (%)
Revenue
42.56% YoY
Q4 2025
Net Income
50.48% YoY
Q4 2025
Net Margin
Q4 2025
Growth Metrics
Profitability Metrics
Technical Analysis
LLY is currently in a technical uptrend phase with institutional accumulation, although price is between key moving averages resulting in some trend uncertainty. Momentum indicators like RSI and ADX suggest a neutral to weak trend environment without strong directional momentum. The 50-day moving average sits above the 200-day, indicating a longer-term bullish bias despite recent price pullbacks.
No extreme reading
Mixed signals
Range-bound market
Watching for cross
Key Technical Values
Price with Moving Averages
50-day, 150-day and 200-day simple moving averages
Relative Strength Index
Momentum oscillator measuring speed and magnitude of price changes
RSI (14)
Earnings
Eli Lilly (LLY) shows exceptionally strong fundamental performance, marked by robust revenue growth, expanding profitability metrics, and a consistent record of earnings beats. The company's innovation-driven product pipeline and leadership in fast-growing therapeutic markets underpin both its current financial health and future prospects, though recent premium valuation demands careful consideration.
Latest Earnings
Q4 2025 Earnings (Dec 31, 2025)
Earnings Per Share (EPS)
Actual
$7.54
Estimated
$6.91
Surprise
+$0.63
Surprise %
+9.12%
Revenue
Actual
$19.29B
Estimated
$17.94B
Surprise
+$1.35B
Surprise %
+7.51%
Historical Earnings
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Earnings Per Share | ||||||||
| EPS (Actual) | $7.54 | $7.02 | $6.31 | $3.34 | $5.32 | $1.18 | $3.92 | $2.58 |
| EPS (Estimated) | $6.91 | $5.69 | $5.60 | $3.26 | $5.03 | $1.47 | $2.60 | $2.46 |
| EPS Surprise | +$0.63 | +$1.33 | +$0.71 | +$0.08 | +$0.29 | -$0.29 | +$1.32 | +$0.12 |
| % Diff | +9.1% | +23.4% | +12.7% | +2.5% | +5.8% | -19.7% | +50.8% | +4.9% |
| Revenue | ||||||||
| Revenue (Actual) | $19.29B | $17.6B | $15.56B | $12.73B | $13.53B | $11.44B | $11.3B | $8.77B |
| Revenue (Estimated) | $17.94B | $16.05B | $14.7B | $12.67B | - | $12.1B | $9.98B | $8.94B |
| Revenue Surprise | +$1.35B | +$1.55B | +$853.57M | +$61.12M | - | -$658.68M | +$1.32B | -$167.78M |
| % Diff | +7.5% | +9.6% | +5.8% | +0.5% | - | -5.4% | +13.2% | -1.9% |
Valuation
Eli Lilly (LLY) is trading at a premium valuation reflecting strong revenue and earnings growth driven by its robust pharmaceutical pipeline, especially in GLP-1 therapies. Analyst consensus remains positive with significant upside price targets, though technical indicators suggest a mixed near-term outlook. Overall, fundamentals substantiate the higher multiples, supported by solid profitability and healthy financial metrics.
Valuation Metrics
Sentiment & Analyst Ratings
Eli Lilly's (LLY) market sentiment is generally positive, driven by the recent FDA approval and U.S. launch of its oral GLP-1 obesity drug, Foundayo, supported by broad distribution partnerships. While analysts mostly maintain buy/outperform ratings with price targets averaging around $1,200, concerns over pricing pressures and emerging competition, particularly generic semaglutide in India, create some mixed views. Retail investor sentiment is cautiously optimistic, focusing on product rollout and anticipated earnings later this month.
Analyst Recommendations
Risk Assessment
Eli Lilly (LLY) demonstrates strong financial health with improving liquidity and manageable leverage amid robust revenue growth driven by its GLP-1 franchise and pipeline expansions. However, the company faces notable risks including competitive pressures from Novo Nordisk, regulatory scrutiny on drug pricing, and ongoing litigation concerns. Market consensus remains optimistic with a strong buy sentiment and attractive upside potential, but the stock trades at a premium reflecting high expectations.
Liquidity & Solvency
Frequently Asked Questions about LLY
AI Answers: Common Questions About LLY
Get AI-powered answers to the questions investors ask most about Eli Lilly and Company
LLY is a good buy for medium- and long-term investors given its 44.7% YoY revenue growth, sector-leading margins (gross >83%, net >31%), and a justified P/E of 41.02. While the stock is consolidating near $939 and below its 50-day SMA, its premium valuation is supported by robust fundamentals and analyst targets around $1,200.
Unless your thesis has changed or you need to reduce exposure, there is no strong reason to sell now. Fundamentals remain strong, and while technicals are neutral in the short term, the long-term growth story is intact. Consider trimming only if you are overexposed or expect near-term volatility to impact your portfolio.
The biggest risks are competitive pressure from Novo Nordisk and generics, regulatory scrutiny on pricing (especially in the US), and ongoing litigation related to GLP-1 drugs. Sentinel notes a debt-to-equity ratio of 1.6 (moderate), but liquidity is strong (current ratio 1.58, quick ratio 1.19), so financial risk is contained.
Analyst price targets average around $1,200, with technical resistance at $985 (50 SMA) and $1,134 (52-week high). Support is at $902 (200 SMA) and $624 (52-week low). A breakout above $985 could trigger a run toward $1,134 and beyond, while a breakdown below $902 would be bearish.
LLY is fairly valued at a P/E of 41.02 and high EV/EBITDA, reflecting its superior growth and profitability compared to peers. While multiples are at the upper end of the sector, they are justified by 40%+ revenue growth and expanding margins, so the stock is not overvalued given its outlook.
LLY is fundamentally strong: revenue and EPS are growing rapidly (EPS up 96% YoY in FY25), gross margin is above 83%, and net margin is over 31%. The balance sheet is solid, with improving liquidity and manageable leverage, supporting ongoing R&D and expansion.
Technically, LLY is consolidating between $900 and $985, with a golden cross (50 SMA above 200 SMA) indicating long-term bullishness. RSI is neutral at 47.56, and ADX is weak at 16.44, suggesting a lack of strong momentum and a wait-and-see approach for short-term traders.
Key catalysts include the Q1 2026 earnings report (April 30), the commercial rollout and uptake of Foundayo, further product launches, and any regulatory or reimbursement policy developments. Watch for volume/momentum shifts around these events as potential inflection points.
Want a Personalized Answer?
Get AI-powered insights tailored to your risk tolerance and investment goals.